Strensiq

Chemical Nameasfotase alfa
Dosage FormInjection (subcutaneous; 18 mg/0.45 mL, 28 mg/0.7 mL, 40 mg/mL, 80 mg/0.8 mL)
Drug ClassMiscellaneous
SystemMusculoskeletal
CompanyAlexion Pharmaceuticals Inc.
Approval Year2015

Indication

  • To treat perinatal, infantile and juvenile-onset hypophosphatasia (HPP).
Last updated on 10/30/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Strensiq (asfotase alfa) Prescribing Information 2018Alexion Pharmaceuticals, Inc., New Haven, CT
Document TitleYearSource
Clinical practice guidelines for hypophosphatasia. 2020Clinical Pediatric Endocrinology